We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Biomarkers Associated With Cardiovascular Outcomes in Psoriatic Patients

By LabMedica International staff writers
Posted on 22 Mar 2022
Print article
Image: In patients with psoriatic disease, cTnI may reflect the burden of atherosclerosis, independent of traditional cardiovascular risk factors (Photo courtesy of Cardiology Advisor)
Image: In patients with psoriatic disease, cTnI may reflect the burden of atherosclerosis, independent of traditional cardiovascular risk factors (Photo courtesy of Cardiology Advisor)

Psoriasis and psoriatic arthritis (PsA), collectively known as psoriatic disease (PsD), are characterized by excess cardiovascular (CV) morbidity and mortality compared to the general population.

Novel laboratory and imaging biomarkers improve CV risk prediction in the general population, and it has been suggested that they could be combined with conventional scoring systems to optimize CV risk stratification.

A group of Medical Scientists working with the Women’s College Hospital (Toronto, ON, Canada) included in a study, a cohort comprised of participants with a diagnosis of psoriasis without arthritis (PsC) followed since 2006, and psoriatic arthritis (PsA) that have been followed prospectively since 1978 as part of a larger study to investigate disease-related outcomes. Among PsA patients, 98% meet the Classification of Psoriatic Arthritis (CASPAR) criteria. PsC patients are enrolled based on a diagnosis of arthritis conformed by a dermatologist and a rheumatologist.

Annual serum samples have been collected and stored in a biobank since 2002, thus patients entered this study at the date they provided their first serum sample. NT-proBNP (Cobas, Roche Diagnostics, Indianapolis, IN, USA) and high-sensitivity cTnI (ARCHITECT STAT, Abbott Laboratories, Abbott Diagnostics, Abbott Park, IL, USA) were measured in serum samples on automated clinically validated immunoassay analyzers using the manufacturers’ calibrators and quality controls. The limit of detection was 5 pg/mL for NT-proBNP and 1.1 pg/mL for cTnI.

The association between cardiac biomarkers and carotid atherosclerosis was assessed by multivariable regression after adjusting for CV risk factors. In univariate analyses, cTnI (β coefficient, 0.52; 95% confidence interval (CI), 0.3-0.74) and NT-proBNP (β coefficient, 0.24; 95% CI, 0.1-0.39) were associated with carotid total plaque area (TPA). After adjusting for CV risk factors, the association remained statistically significant for cTnI (adjusted β coefficient, 0.21; 95% CI, 0-0.41), but not NT-proBNP. Among all the 1,000 patients in the study who were assessed for CV risk prediction, 64 patients had incident CV events. When comparing a base model with the Framingham Risk Score alone versus expanded models that included the Framingham Risk Score plus cardiac biomarkers, there was no improvement in predictive performance.

The authors concluded that in patients with psoriatic disease (PsD), cTnI may reflect the burden of atherosclerosis, independent of traditional CV risk factors. cTnI and NT-proBNP are associated with incident CV events independent of the Framingham Risk Score (FRS), however, further study of their role in CV risk stratification is warranted. The study was published on march 8, 2022 in the journal Arthritis & Rheumatology.

Related Links:
Women’s College Hospital 
Roche Diagnostics 
Abbott Diagnostics 

Gold Supplier
Nucleic Acid Extraction System
3-Part Diff Hematology Analyzer
Automatic Hematology Analyzer
SARS-CoV-2 IgG Antibodies Anti-S1 Assay
iRapid SARS-CoV-2 Quant "Neutralizing" Ab

Print article


Molecular Diagnostics

view channel
Image: This image depicts a DNA molecule that is methylated on both strands on the center cytosine. DNA methylation plays an important role for epigenetic gene regulation in development and cancer (Photo courtesy of Wikimedia Commons)

Study Supports Use of Methylated DNA Biomarkers for Cancer Diagnosis and Prognosis

A recent study added weight to the theory that methylated DNA biomarkers could be used for cancer diagnosis and prognosis. Methylation is a biological process by which methyl groups are added to a DNA molecule.... Read more


view channel
Image: Standard test for multiple myeloma provides clues of a rare, more deadly type (Photo courtesy of Pexels)

Standard Blood Cancer Test Provides Clues of Rare IgD Multiple Myeloma

IgD myeloma accounts for about 1% of common blood cancer multiple myeloma and has a worse prognosis. Specific testing for IgD myeloma is available at a handful of reference labs across the US, but takes... Read more


view channel
Image: QIAGEN has acquired a majority stake in enzymes provider BLIRT S.A. (Photo courtesy of QIAGEN)

Qiagen Acquires Enzymes Provider Blirt to Strengthen Sample Technologies Business

QIAGEN N.V. (Venlo, Netherlands) has signed agreements to acquire a 96% majority ownership stake in BLIRT S.A. (Gdansk, Poland), a manufacturer of recombinant enzymes for the life science industry.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.